Mirum Pharmaceuticals (MIRM) News Today $49.63 +0.61 (+1.24%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$49.66 +0.02 (+0.05%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MIRM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Brokers Set Expectations for MIRM FY2026 EarningsMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Mirum Pharmaceuticals in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earJune 11, 2025 | marketbeat.comAnalysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $60.73June 11, 2025 | americanbankingnews.comMirum Pharmaceuticals Inc.June 11, 2025 | barrons.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 10, 2025 | businesswire.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Buy" from AnalystsMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has been given an average rating of "Buy" by the twelve ratings firms that are currently covering the company, MarketBeat reports. Ten research analysts have rated the stock with a buy recommendation and two have given a strong buy recommeJune 8, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.06 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 16.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. ThJune 6, 2025 | marketbeat.comSecure Asset Management LLC Purchases 8,990 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Secure Asset Management LLC lifted its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 22.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 48,910 shares of the company's stock after acquiring an additioJune 4, 2025 | marketbeat.comSquarepoint Ops LLC Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Squarepoint Ops LLC acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 21,682 shares of the company's stoJune 2, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Position Decreased by Two Sigma Investments LPTwo Sigma Investments LP cut its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 44.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,446 shares of the company'sMay 29, 2025 | marketbeat.comMan Group plc Invests $289,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Man Group plc acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 6,989 shares of the company's stock, valued at approximately $289,000. Several otherMay 29, 2025 | marketbeat.comMirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potentialMay 27, 2025 | investing.comVoloridge Investment Management LLC Sells 85,242 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Voloridge Investment Management LLC cut its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 33.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 171,537 shares of the company's stock after selling 85,242 shares during the quarter. VolMay 27, 2025 | marketbeat.comTwo Sigma Advisers LP Trims Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Two Sigma Advisers LP trimmed its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 15.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 174,400 shares of the company's stock after selling 31,100 shares duMay 26, 2025 | marketbeat.comWoodline Partners LP Acquires 73,399 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Woodline Partners LP increased its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 22.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 404,404 shares of the compMay 24, 2025 | marketbeat.comNuveen Asset Management LLC Has $29.86 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Nuveen Asset Management LLC raised its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 46.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 722,155 shares of the companyMay 24, 2025 | marketbeat.comEquities Analysts Offer Predictions for MIRM Q2 EarningsMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 EPS estimates for Mirum Pharmaceuticals in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst S. Ramakanth forecasts that the company willMay 23, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Rafferty Asset Management LLCRafferty Asset Management LLC decreased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 47.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,160 shares of the company's stock after selling 40,May 23, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Millennium Management LLCMillennium Management LLC grew its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 15.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 526,974 shares of the company's stock after acquiring an additional 71,410 shares duringMay 23, 2025 | marketbeat.comMirum Pharmaceuticals at RBC Conference: Strategic Growth HighlightsMay 22, 2025 | uk.investing.comHC Wainwright Reaffirms Buy Rating for Mirum Pharmaceuticals (NASDAQ:MIRM)HC Wainwright restated a "buy" rating and set a $73.00 target price on shares of Mirum Pharmaceuticals in a report on Monday.May 21, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Tang Capital Management LLCTang Capital Management LLC cut its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 3.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,237,107 shares of the company's stock after seMay 20, 2025 | marketbeat.comTema Etfs LLC Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Tema Etfs LLC purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,968 shares of the company's sMay 20, 2025 | marketbeat.comDeutsche Bank AG Has $7 Million Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Deutsche Bank AG lifted its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 7.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 169,323 shares of the company's stock after buying anMay 20, 2025 | marketbeat.comMirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal OfficerMay 19, 2025 | businesswire.comD. E. Shaw & Co. Inc. Purchases Shares of 157,352 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)D. E. Shaw & Co. Inc. purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 157,352 shares of the company's stock, valued at approximately $6,507,May 18, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Prosight Management LPProsight Management LP lowered its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 3.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 451,127 shares of the company's stock after selling 14,698 shares during the periMay 17, 2025 | marketbeat.comBalyasny Asset Management L.P. Purchases New Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Balyasny Asset Management L.P. purchased a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 18,733 shares of the company's stock, valued at approximately $77May 17, 2025 | marketbeat.comNorthern Trust Corp Acquires 32,059 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Northern Trust Corp grew its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 8.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 399,544 shares of the company's stock after purchasing an additional 32,059 sharMay 17, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by MPM Bioimpact LLCMPM Bioimpact LLC raised its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 19.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 589,579 shares of the company's stock after acquiMay 16, 2025 | marketbeat.comPatient Square Capital LP Buys Shares of 64,900 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Patient Square Capital LP bought a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 64,900 shares of the company's stock, valued at approximately $2,684,000. MirumMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 51.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,May 16, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by BrokeragesMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has been given a consensus recommendation of "Buy" by the twelve research firms that are presently covering the firm, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation and two have asMay 16, 2025 | marketbeat.comMirum Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 14, 2025 | businesswire.comJanus Henderson Group PLC Has $189.48 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Janus Henderson Group PLC grew its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 2.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 4,581,642 shares of the company's stock after buying an additional 101,358 shares duringMay 14, 2025 | marketbeat.comCubist Systematic Strategies LLC Sells 14,797 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Cubist Systematic Strategies LLC reduced its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 15.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 83,969 shares of the company's stock after selMay 13, 2025 | marketbeat.comFY2025 EPS Estimates for MIRM Raised by Cantor FitzgeraldMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Stock analysts at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for shares of Mirum Pharmaceuticals in a research note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst J. Schimmer now forecasts thatMay 13, 2025 | marketbeat.comLeerink Partnrs Brokers Increase Earnings Estimates for MIRMMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Equities researchers at Leerink Partnrs boosted their Q2 2025 earnings per share estimates for shares of Mirum Pharmaceuticals in a research note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst M. Foroohar now expects thMay 13, 2025 | marketbeat.com6,504 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Bought by Hsbc Holdings PLCHsbc Holdings PLC acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 6,504 shares of the company's stock, valuedMay 12, 2025 | marketbeat.comAlgert Global LLC Invests $2.82 Million in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Algert Global LLC acquired a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 68,291 shares of the company'May 10, 2025 | marketbeat.comMirum Pharmaceuticals (MIRM) Expected to Announce Quarterly Earnings on WednesdayMirum Pharmaceuticals (NASDAQ:MIRM) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-mirum-pharmaceuticals-inc-stock/)May 9, 2025 | marketbeat.comTudor Investment Corp ET AL Makes New Investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Tudor Investment Corp ET AL bought a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 23,966 shares of the company's stock, valued at approMay 9, 2025 | marketbeat.comBoone Capital Management LLC Raises Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Boone Capital Management LLC lifted its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 7.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 581,843 shares of the company's stock after acquiriMay 8, 2025 | marketbeat.comMirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...May 8, 2025 | finance.yahoo.comMirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growthMay 8, 2025 | msn.comMirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comMirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | finance.yahoo.comMirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | finance.yahoo.comPreview: Mirum Pharmaceuticals's EarningsMay 6, 2025 | benzinga.comAvidity Partners Management LP Sells 64,904 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Avidity Partners Management LP trimmed its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 8.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 666,200 shares of the company's stockMay 6, 2025 | marketbeat.comBVF Inc. IL Has $115.64 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)BVF Inc. IL cut its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 9.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,796,513 shares of the company's stock after selling 279,394 sMay 6, 2025 | marketbeat.com Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address MIRM Media Mentions By Week MIRM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIRM News Sentiment▼0.980.89▲Average Medical News Sentiment MIRM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIRM Articles This Week▼85▲MIRM Articles Average Week Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Blueprint Medicines News Today Roivant Sciences News Today Revolution Medicines News Today BridgeBio Pharma News Today Elanco Animal Health News Today Verona Pharma News Today Legend Biotech News Today TG Therapeutics News Today Grifols News Today Lantheus News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIRM) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MIRM Stock Free MIRM Stock Alerts